Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Prof. Alessio Cantore, The Telethon Foundation and San Raffaele Hospital. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and backed by Sofinnova Partners.

Biopharmaceuticals

Graziano Seghezzi & Lucia Faccio

Graziano Seghezzi is Managing Partner at Sofinnova Partners which he joined in 2006. He seed funded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals ...

 

Lucia Faccio joined Sofinnova Partners in 2018 as Partner for the Sofinnova Telethon Fund, Italy’s first biotechnology fund focused on rare and genetic diseases. Since 2012, she has been Director of Research & Development at Fondazione Telethon, ...